Literature DB >> 7432527

3H-apomorphine labels both dopamine postsynaptic receptors and autoreceptors.

P Sokoloff, M P Martres, J C Schwartz.   

Abstract

Evidence points to the existence of multiple classes of dopamine (DA) receptor in mammalian brain which can be distinguished by their pharmacological specificities and localizations, and by the actions they mediate. Among them, dopaminergic autoreceptors are regulatory receptors presumed to be present in the membrane of the DA neurones themselves, and believed to mediate an inhibition of these neurones' activity, either at nerve endings or on cell bodies. However, the pharmacology of autoreceptors remains to be established because attempts to characterize autoreceptors by 3H-ligand binding techniques have produced controversial data. Thus Seeman and co-workers stated that 3H-apomorphine selectively labels autoreceptors, whereas Creese et al. concluded that this ligand selectively labels postsynaptic DA receptors. In addition, large differences in the capacity and drug specificity of 3H-apomorphine receptor sites in rat striatum have been reported. We demonstrate here that 3H-apomorphine labels two classes of DA receptor, distinguishable using domperidone, a selective DA antagonist. Lesion studies indicate that they correspond to a certain class of postsynaptic receptor and to autoreceptors, respectively. Each of these classes displays a clearly distinct pharmacological specificity for antipsychotics and DA agonists.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7432527     DOI: 10.1038/288283a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  15 in total

1.  Autoradiographic localisation of 3H-apomorphine binding sites in rat brain.

Authors:  M L Bouthenet; N Sales; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-07       Impact factor: 3.000

2.  Apomorphine anorexia: a behavioural and neuropharmacological analysis.

Authors:  P Willner; A Towell; R Muscat
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

3.  Pharmacological characterization of the receptors involved in the apomorphine-induced polyphasic modifications of locomotor activity in mice.

Authors:  P Protais; J J Bonnet; J Costentin
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

4.  Possible mechanism of prolactin unresponsiveness to repeated sulpiride administration in man.

Authors:  G P Bernini; M Gasperi; M S Vivaldi; R Santoni; M Luisi; F Franchi
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Dopaminergic binding sites in rat striatal slices and the action of guanyl nucleotides.

Authors:  M P Martres; P Sokoloff; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

6.  Interaction of the component enantiomers of the putative dopamine autoreceptor agonist, TL-99 (6,7-dihydroxy-2-dimethylamino tetralin) with dopaminergic systems in mammalian brain and teleost retina.

Authors:  M Williams; G E Martin; D E McClure; J J Baldwin; K J Watling
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-12       Impact factor: 3.000

7.  Action of apomorphine, bromocriptine and lergotrile on gamma-aminobutyric acid and acetylcholine release in nucleus accumbens and corpus striatum.

Authors:  J de Belleroche; I M Gardiner
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

8.  Selection of dopamine antagonists discriminating various behavioral responses and radioligand binding sites.

Authors:  M P Martres; P Sokoloff; M Delandre; J C Schwartz; P Protais; J Costentin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

9.  Effect of a stereospecific D2-dopamine agonist on acetylcholine concentration in corpus striatum of rat brain.

Authors:  D T Wong; F P Bymaster; L R Reid; R W Fuller; K W Perry; E C Kornfeld
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

10.  Pharmacological effects of Ro 22-1319: a new antipsychotic agent.

Authors:  A B Davidson; E Boff; D A MacNeil; J Wenger; L Cook
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.